

# Cytogen

[View the current Cytogen Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3174-Cytogen.html)

(<http://www.bioportfolio.com/biocorporate/3174-Cytogen.html>)

## Contact Details:

**650 College Road East**

**Princeton**

**NJ**

**08540**

**United States of America**

Tel: (800) 833-3533 or (609) 750-8200

Fax: (609) 452-2476

Email:

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer, and SOLTAMOX is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. In early 2007, Cytogen introduced its fourth approved oncology product to the U.S. market, CAPHOSOL®, an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy focuses on attaining sustainable growth through clinical, commercial, and strategic initiatives.

## Recent Publications by Cytogen:



- [Cytogenetic study of professional rescue rangers of Russian Ministry of Emergencies.](#)  
*Cytogenetic studies in rescue rangers of the Russian Ministry of...*3rd October, 2008  
A. M. Nikiforov National Center of Urgent and Radiation Medicine, Ministry- Bull Exp Biol Med. 2007 Oct;144(4):555-8.
- [Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family.](#)  
*Familial Tumoral Calcinosis (FTC) is a rare autosomal recessive disorder...*10th September, 2008  
Unite de Biologie Humaine, Faculte des Sciences de la Sante, Cotonou,- Genet Couns. 2008;19(2):183-92.

- [Indium-111 capromab pendetide in the management of recurrent prostate cancer.](#)  
*The provision of accurate prognostic information is a long-standing goal...*28th March, 2008  
The George Washington University, Washington, DC, 650 College Road East,- Expert Rev Anticancer Ther. 2008 Feb;8(2):175-81. ([DOI Direct Link](#))
- [The emergence of imaging technology in advanced prostate cancer.](#)  
*Rapid advances in imaging technology have whetted our collective appetites...*7th March, 2008  
Department of Medical Affairs, Cytogen Corporation, Princeton, NJ, USA.- Can J Urol. 2007 Dec;14 Suppl 1:32-8.
- [Wolf Hirshhorn syndrome in a case of ring chromosome 4: phenotype and molecular cytogenetic findings.](#)  
*Ring chromosome 4 associates concomitant loss of the telomeric 4p and 4q...*17th October, 2006  
Unite de Biologie Humaine, Faculte des Sciences de la Sante, Cotonou,- Genet Couns. 2006;17(1):35-40.
- [The evolution of imaging in advanced prostate cancer.](#)  
*Medical advances will be driven by the enhancement of imaging for...*29th July, 2006  
Cytogen- Urol Clin North Am. 2006 May;33(2):133-46, v. ([DOI Direct Link](#))
- [Chromosome alterations in cleanup workers sampled years after the Chernobyl accident.](#)  
*Cytogenetic analysis performed 4-13 years after the Chernobyl accident...*9th August, 2003  
All Russian Centre of Emergency and Radiation Medicine, Laboratory of- Radiat Res. 2003 Jul;160(1):46-51.
- [Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones.](#)  
*The retinoic acid (RA)-sensitive NB4 cell line was the first established...*26th November, 2002  
Institut Paoli-Calmettes and INSERM U119, Marseille, France.- Genes Chromosomes Cancer. 2002 Nov;35(3):261-70. ([DOI Direct Link](#))
- [Cytogenetic investigation of occupationally irradiated persons a long time after exposure.](#)  
*Chromosomal analyses were performed in blood lymphocytes of 33 persons...*25th July, 2000  
All Russian Center of Emergency and Radiation Medicine, Emercom of Russia,- Appl Radiat Isot. 2000 May;52(5):1161-4.

#### Press Releases on Cytogen:

[Reportlinker Adds  
Imaging Agents - A  
Worldwide Market  
Review](#)

20th November, 2009  
Reportlinker

NEW YORK, Nov. 20 /PRNewswire/ --  
Reportlinker.com announces that a new market  
research report is available in its catalogue.  
Imaging Agents - A Worldwide Market Review  
<http://www.reportlinker.com>

[Long-term Outcomes  
Data Validates the  
Utility of  
PROTASCINT in  
Guiding Targeted  
Prostate Cancer  
Treatment and  
Predicting Disease  
Free Survival](#)

4th November, 2009  
EUSA Pharma  
(USA), Inc.

LANGHORNE, Pa., Nov. 4 /PRNewswire/ --  
EUSA Pharma announced that  
PROTASCINTÂ® (capromab pendetide) fusion  
imaging was shown to effectively guide prostate  
cancer therapy targeting and dosing and is a

<a href="#">New Report Just Published: World Prostate Cancer Therapeutics Market Report</a>	7th July, 2009	Reportlinker	NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Prostate Cancer Therapeutics Market <a href="http://www.reportlinker.com/p0119471/World">http://www.reportlinker.com/p0119471/World</a>
<a href="#">DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller</a>	7th July, 2009	DOR BioPharma, Inc.	PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently
<a href="#">Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer</a>	26th May, 2009	Strategic Diagnostics Inc.	NEWARK, Del., May 26 /PRNewswire-FirstCall/ -- Strategic Diagnostics Inc. (Nasdaq: SDIX) - today announced that Kevin J. Bratton has joined the Company as its Vice President of Finance and Chief

## BioNews Results for Cytogen



- [CNS Protein Therapeutics Completes Name Change to Amaranthus Therapeutics, Appoints New CEO Martin D. Cleary](#)  
*Pharma Live: Oct 30 2009 10:55PM Matching: cytogen*
- [CNS Protein Therapeutics changes its corporate name to Amaranthus Therapeutics](#)  
*News-Medical.Net: Oct 29 2009 8:45AM Matching: cytogen*
- [CNS Protein Therapeutics Completes Name Change to Amaranthus Therapeutics, Appoints New CEO Martin D. Cleary](#)  
*Genetic Engineering News: Oct 28 2009 6:24PM Matching: cytogen*

## Cytogen Clinical Trials:



- [Safety Study of a Radiolabeled Antibody \(7E11\) in Patients With Progressive Hormone Refractory Prostate Cancer](#)



## Cytogen Patents:

- 7279548- [Identification and isolation of novel polypeptides having WW domains and methods of using same](#)
- 5527885- [Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding](#)
- 5495042- [Non-alkaline purification of aminophosphonic acids](#)
- 5449761- [Metal-binding targeted polypeptide constructs](#)
- 5326856- [Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding](#)
- 5196510- [Molecular recognition units](#)
- 5162512- [Amine derivatives of anthracycline antibodies](#)
- 5162504- [Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients](#)
- 5156840- [Amine-containing porphyrin derivatives](#)
- 5140104- [Amine derivatives of folic acid analogs](#)
- 5047227- [Novel and improved antibodies for site specific attachment of compounds](#)
- 4966999- [Radiohalogenated compounds for site specific labeling](#)
- 4950738- [Amine derivatives of anthracycline antibiotics](#)
- 4937183- [Method for the preparation of antibody-fragment conjugates](#)
- 4867973- [Antibody-therapeutic agent conjugates](#)
- 4853326- [Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic prophylactic and/or therapeutic applications](#)
- 4741900- [Antibody-metal ion complexes](#)
- 5578288- [Metal-binding targeted polypeptide constructs](#)
- 5578484- [Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells](#)
- 7223547- [Polypeptides having a functional domain of interest and methods of identifying and using same](#)
- 7135457- [Random peptides that bind to gastro-intestinal tract \(GIT\) transport receptors and related methods](#)
- 7053177- [Random peptides that bind to gastro-intestinal tract \(GIT\) transport receptors and related methods](#)
- 6709821- [Polypeptides having a functional domain of interest and methods of identifying and using same](#)
- 6703362- [Random peptides that bind to gastro-intestinal tract \(GIT\) transport receptors and related methods](#)
- 6432920- [Nck SH3 binding peptides](#)
- 6309820- [Polypeptides having a functional domain of interest and methods of identifying and using same](#)
- 6184205- [GRB2 SH3 binding peptides and methods of isolating and using same](#)
- 6015561- [Antigen binding peptides \(abptides\) from peptide libraries](#)
- 6011137- [Identification and isolation of novel polypeptides having WW domains and methods of using same](#)
- 5942210- [Methods for lyoprotecting a macromolecule using tricine](#)
- 5885577- [Antigen binding peptides \(abptides\) from peptide libraries](#)
- 5763202- [Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells](#)
- 5609847- [Treatment methods using metal-binding targeted polypeptide constructs](#)

- 5593656- [Metal-binding targeted polypeptide constructs](#)
- 5585468- [Substituted thioureas as bifunctional chelators](#)
- 4671958- [Antibody conjugates for the delivery of compounds to target sites](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

